Within the PD-(L)1 class, Keytruda is responsible for over 55% of the total global sales. Its current revenue total makes ...

Researchers conducted a nationwide cohort study using data from the Taiwan National Health Insurance database and the Taiwan ...

A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery ...

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk ...

However, the landscape began to shift with the development of immune checkpoint inhibitors, which release "the brakes" on immune cells, freeing them to attack cancer cells. When combined with ...

As many as 40% of cancer patients receiving immune checkpoint inhibitors experience immune-related adverse events.